UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22

The Journal of experimental medicine, 2014-07, Vol.211 (8), p.1571-1583

2014

Volltextzugriff (PDF)

Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review

Journal of medical Internet research, 2019-08, Vol.21 (8), p.e14630-e14630

2019

Volltextzugriff (PDF)

Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease

PloS one, 2012-07, Vol.7 (7), p.e41594-e41594

2012

Volltextzugriff (PDF)

Adherent-invasive E. coli metabolism of propanediol in Crohn’s disease regulates phagocytes to drive intestinal inflammation

Cell host & microbe, 2021-04, Vol.29 (4), p.607-619.e8

2021

Volltextzugriff (PDF)

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Journal of Crohn's and colitis, 2022-08, Vol.16 (8), p.1222-1234

2022

Volltextzugriff (PDF)

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy

Alimentary pharmacology & therapeutics, 2020-12, Vol.52 (11-12), p.1658-1675

2020

Volltextzugriff (PDF)

Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation

Inflammatory bowel diseases, 2014-11, Vol.20 (11), p.1919-1932

2014

Volltextzugriff (PDF)

Short Chain Fatty Acids Modulate the Growth and Virulence of Pathosymbiont Escherichia coli and Host Response

Antibiotics (Basel), 2020-08, Vol.9 (8), p.462

2020

Volltextzugriff (PDF)

5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity

Journal of antibiotics, 2018-11, Vol.71 (11), p.950-961

2018

Volltextzugriff (PDF)

Management of Primary Sclerosing Cholangitis and Extraintestinal Disorders in Patients With Ileal Pouches: A Systematic Review

Diseases of the colon & rectum, 2024-06, Vol.67 (S1), p.S106

2024

Volltextzugriff (PDF)

Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux Pumps

Antimicrobial Agents and Chemotherapy, 2013-02, Vol.57 (2), p.811-817

2013

Volltextzugriff (PDF)

Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses

Journal of antibiotics, 2018-05, Vol.71 (5), p.485-494

2018

Volltextzugriff (PDF)

Immune regulation by fungal strain diversity in inflammatory bowel disease

Nature (London), 2022-03, Vol.603 (7902), p.672-678

2022

Volltextzugriff (PDF)

ID1 Is a Functional Marker for Intestinal Stem and Progenitor Cells Required for Normal Response to Injury

Stem cell reports, 2014-11, Vol.3 (5), p.716-724

2014

Volltextzugriff (PDF)

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

Gastroenterology (New York, N.Y. 1943), 2020-10, Vol.159 (4), p.1541-1544.e2

2020

Volltextzugriff (PDF)

Mucosal metabolites fuel the growth and virulence of E. coli linked to Crohn's disease

JCI insight, 2022-05, Vol.7 (10)

2022

Volltextzugriff (PDF)

Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis

Immunity (Cambridge, Mass.), 2018-12, Vol.49 (6), p.1077-1089.e5

2018

Volltextzugriff (PDF)

Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease

World journal of gastroenterology : WJG, 2022-09, Vol.28 (33), p.4834-4845

2022

Volltextzugriff (PDF)

S719 Maternal and Neonatal Outcomes in Vedolizumab and Ustekinumab Exposed Pregnancies: Results From the PIANO Registry

The American journal of gastroenterology, 2022-10, Vol.117 (10S), p.e502-e503

2022

Volltextzugriff (PDF)

Ulcerative Colitis Care Pathway

Gastroenterology (New York, N.Y. 1943), 2015-07, Vol.149 (1), p.238-245

2015

Volltextzugriff (PDF)

Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry

The American journal of gastroenterology, 2024-03, Vol.119 (3), p.468-476

2024

Volltextzugriff (PDF)

Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease

Inflammatory bowel diseases, 2021-08, Vol.27 (9), p.1443-1451

2021

Volltextzugriff (PDF)

Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination

Clinical gastroenterology and hepatology, 2022-06, Vol.20 (6), p.e1493-e1499

2022

Volltextzugriff (PDF)

Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease

Inflammatory bowel diseases, 2022-12, Vol.28 (12), p.1865-1871

2022

Volltextzugriff (PDF)

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study

Clinical gastroenterology and hepatology, 2021-11, Vol.19 (11), p.2324-2332.e6

2021

Volltextzugriff (PDF)

1 – 25 von 258

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(170)
Mit Volltextzugriff
(223)

Publikationsform

Artikel
(172)
Buchkapitel
(79)
Berichte
(4)
Bücher
(3)

Sprache

Englisch
(258)

Erscheinungsjahr

n.n

Thema

15 weitere anzeigen...

Weniger anzeigen...

Menü

Weitere Dienste

Einstellungen

CX₃CR1⁺ mononuclear phagocytes support colitis-associated innate lymphoid cell production of IL-22

Digital Health Apps in the Clinical Care of Inflammatory Bowel Disease: Scoping Review

Inflammation drives dysbiosis and bacterial invasion in murine models of ileal Crohn's disease

Adherent-invasive E. coli metabolism of propanediol in Crohn’s disease regulates phagocytes to drive intestinal inflammation

Efficacy and Safety of Maintenance Ustekinumab for Ulcerative Colitis Through 3 Years: UNIFI Long-term Extension

Ustekinumab is effective and safe for ulcerative colitis through 2 years of maintenance therapy

Inflammation-associated adherent-invasive Escherichia coli are enriched in pathways for use of propanediol and iron and M-cell translocation

Short Chain Fatty Acids Modulate the Growth and Virulence of Pathosymbiont Escherichia coli and Host Response

5-Aminosalicylic acid downregulates the growth and virulence of Escherichia coli associated with IBD and colorectal cancer, and upregulates host anti-inflammatory activity

Management of Primary Sclerosing Cholangitis and Extraintestinal Disorders in Patients With Ileal Pouches: A Systematic Review

Rifaximin Resistance in Escherichia coli Associated with Inflammatory Bowel Disease Correlates with Prior Rifaximin Use, Mutations in rpoB, and Activity of Phe-Arg-β-Naphthylamide-Inhibitable Efflux Pumps

Rifaximin decreases virulence of Crohn's disease-associated Escherichia coli and epithelial inflammatory responses

Immune regulation by fungal strain diversity in inflammatory bowel disease

ID1 Is a Functional Marker for Intestinal Stem and Progenitor Cells Required for Normal Response to Injury

Baseline Disease Activity and Steroid Therapy Stratify Risk of COVID-19 in Patients With Inflammatory Bowel Disease

Mucosal metabolites fuel the growth and virulence of E. coli linked to Crohn's disease

Microbiota-Induced TNF-like Ligand 1A Drives Group 3 Innate Lymphoid Cell-Mediated Barrier Protection and Intestinal T Cell Activation during Colitis

Prevalence and factors associated with vitamin C deficiency in inflammatory bowel disease

S719 Maternal and Neonatal Outcomes in Vedolizumab and Ustekinumab Exposed Pregnancies: Results From the PIANO Registry

Ulcerative Colitis Care Pathway

Maternal and Neonatal Outcomes in Vedolizumab- and Ustekinumab-Exposed Pregnancies: Results From the PIANO Registry

Immunogenicity of Tumor Necrosis Factor Antagonists and Effect of Dose Escalation on Anti-Drug Antibodies and Serum Drug Concentrations in Inflammatory Bowel Disease

Impact of Inflammatory Bowel Disease Therapies on Durability of Humoral Response to SARS-CoV-2 Vaccination

Utility of Therapeutic Drug Monitoring for Tumor Necrosis Factor Antagonists and Ustekinumab in Postoperative Crohn's Disease

Anti-TL1A Antibody PF-06480605 Safety and Efficacy for Ulcerative Colitis: A Phase 2a Single-Arm Study

Suchergebnisse filtern